MLTX

17.13

0.59% 0.10

Dopo l'orario di chiusura: 17.12 -0.010 -0.06%

Moonlake Immunotherapeutics (MLTX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché MLTX Giù? Forum Previsione

Precedente Chiudi:

$17.03

Aprire:

$17.14

Volume 24 ore:

678.58K

Relative Volume:

0.34

Capitalizzazione di mercato:

$1.23B

Reddito:

Utile/perdita netta:

$-230.32M

Rapporto P/E:

-4.8583

EPS:

-3.5259

Flusso di cassa netto:

$-196.04M

1 W Prestazione:

-5.62%

1M Prestazione:

+8.62%

6M Prestazione:

-67.45%

1 anno Prestazione:

-54.71%

Intervallo 1D:

$17.06

$17.79

Intervallo di 1 settimana:

$16.97

$19.34

Portata 52W:

$5.95

$62.75

Moonlake Immunotherapeutics Stock (MLTX) Company Profile

Nome

Moonlake Immunotherapeutics

Settore

Healthcare (1116)

Industria

Biotechnology (621)

Telefono

41 41 510 8022

Indirizzo

DORFSTRASSE 29, ZUG

Dipendente

130

Cinguettio

Prossima data di guadagno

2024-11-12

Ultimi documenti SEC

MLTX's Discussions on Twitter

Compare MLTX vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
MLTX Moonlake Immunotherapeutics	17.13	1.23B	0	-230.32M	-196.04M	-3.5259
VRTX Vertex Pharmaceuticals Inc	469.34	119.23B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	745.77	78.84B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	700.45	43.35B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	313.41	41.57B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	284.05	31.51B	5.36B	287.73M	924.18M	2.5229

Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-01-15	Downgrade	Goldman	Neutral → Sell
2026-01-09	Aggiornamento	BTIG Research	Neutral → Buy
2025-11-03	Aggiornamento	H.C. Wainwright	Neutral → Buy
2025-10-02	Downgrade	H.C. Wainwright	Buy → Neutral
2025-10-01	Downgrade	Goldman	Buy → Neutral
2025-09-30	Downgrade	Citigroup	Buy → Neutral
2025-09-30	Downgrade	Wolfe Research	Outperform → Underperform
2025-09-29	Downgrade	BTIG Research	Buy → Neutral
2025-09-29	Downgrade	Jefferies	Buy → Hold
2025-09-29	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2025-09-29	Downgrade	Stifel	Buy → Hold
2025-07-28	Iniziato	Rothschild & Co Redburn	Neutral
2025-05-19	Aggiornamento	Wolfe Research	Peer Perform → Outperform
2025-03-18	Iniziato	RBC Capital Mkts	Outperform
2025-01-17	Aggiornamento	Goldman	Neutral → Buy
2024-11-05	Ripresa	Wedbush	Outperform
2024-08-26	Downgrade	Wolfe Research	Outperform → Peer Perform
2024-06-25	Iniziato	Oppenheimer	Outperform
2024-04-02	Iniziato	Goldman	Neutral
2024-02-15	Iniziato	Wolfe Research	Outperform
2023-12-08	Iniziato	Citigroup	Buy
2023-11-02	Iniziato	Stifel	Buy
2023-09-14	Downgrade	Bryan Garnier	Buy → Neutral
2023-08-31	Iniziato	Needham	Buy
2023-06-15	Iniziato	Barclays	Equal Weight
2023-05-01	Iniziato	Guggenheim	Buy
2023-03-22	Iniziato	Wedbush	Outperform
2023-03-09	Iniziato	BTIG Research	Buy
2023-02-14	Iniziato	Cantor Fitzgerald	Overweight
2023-02-02	Iniziato	Bryan Garnier	Buy
2022-11-11	Iniziato	Jefferies	Buy
2022-08-25	Iniziato	SVB Leerink	Outperform
2022-07-21	Iniziato	H.C. Wainwright	Buy
2022-07-07	Iniziato	Cowen	Outperform

Mostra tutto

Moonlake Immunotherapeutics Borsa (MLTX) Ultime notizie

Mar 13, 2026

TD Cowen Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating - 富途牛牛

Mar 13, 2026

MLTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Mar 13, 2026

Mar 11, 2026

MoonLake price target raised to $70 from $45 at Clear Street - TipRanks

Mar 11, 2026

Clear Street raises Moonlake stock price target on IL-17 data By Investing.com - Investing.com Australia

Mar 11, 2026

Clear Street raises Moonlake stock price target on IL-17 data - Investing.com

Mar 11, 2026

Mar 10, 2026

How Investors Are Reacting To MoonLake Immunotherapeutics (MLTX) Widening Annual Net Loss Amid Share Price Gains - simplywall.st

Mar 10, 2026

Mar 09, 2026

Trading the Move, Not the Narrative: (MLTX) Edition - Stock Traders Daily

Mar 09, 2026

Mar 08, 2026

MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout - MSN

Mar 08, 2026

Mar 07, 2026

Is MoonLake Immunotherapeutics stock a smart buy before Fed meeting2026 EndofMonth & Verified Short-Term Trading Plans - Naître et grandir

Mar 07, 2026

TD Asset Management Inc Lowers Holdings in MoonLake Immunotherapeutics $MLTX - MarketBeat

Mar 07, 2026

MoonLake stock soars as biotech fund reloads, takeover chatter ignites - MSN

Mar 07, 2026

Mar 06, 2026

Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Positive Phase 2 Sonelokimab Results - simplywall.st

Mar 06, 2026

Mar 05, 2026

MoonLake Therapeutics Stock Sparks Retail Frenzy Ahead Of New York Summit — Traders See 'Nonstop Catalysts' Through 2026 - Stocktwits

Mar 05, 2026

HC Wainwright Issues Negative Outlook for MLTX Earnings - MarketBeat

Mar 05, 2026

Mar 04, 2026

What is HC Wainwright's Estimate for MLTX FY2027 Earnings? - MarketBeat

Mar 04, 2026

Mar 03, 2026

Wedbush Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $34 - 富途牛牛

Mar 03, 2026